Researchers at Moffitt Cancer Center have developed a new chemical method that could make targeted cancer drugs safer and more effective. The discovery focuses on improving how these drugs bind to proteins that drive cancer growth.
Targeted cancer drugs are designed to attack specific proteins in cancer cells. However, they sometimes also bind to other proteins in the body, leading to unwanted side effects. The new approach allows scientists to design drugs that attach more selectively to cancer-related proteins, while avoiding these off-target interactions.
This method could be especially useful for lung cancer treatments, where precision is important to control tumors without harming healthy cells. By reducing side effects, patients may tolerate the therapy better and receive more effective treatment.
The researchers believe this chemical strategy can be applied to many different targeted drugs, not just those for lung cancer. The work represents a step forward in making cancer medicines both more powerful and safer for patients.
The team at Moffitt Cancer Center continues to study how this approach can be optimized for future drug development.